Research Article
Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
Table 3
Utility values used in the model.
| | | Mean (SE) | Source |
| | Utility values for PFS and PPS, mean (SE) | | | | Preprogression | | | | Pazopanib | 0.674 (0.015) | PALETTE | | Placebo | 0.678 (0.024) | PALETTE | | Postprogression | | | | Pazopanib | 0.568 (0.044) | PALETTE | | Placebo | 0.636 (0.040) | PALETTE | | Estimated disutility values for AEs (SE) | | | | Alopecia | 0.045 (0.015) | Nafees et al. 2008 [27] | | Anemia/hemoglobin | 0.119 (0.023) | Swinburn et al. 2010 [28] | | Asthenia/fatigue | 0.262 (0.027) | Shingler et al. 2013 [26] | | Cardiovascular (cardiac toxicity/left ventricular dysfunction) | 0.2 (0) | Assumption | | Decreased appetite/anorexia/weight decreased | 0.2 (0) | Assumption | | Diarrhea | 0.327 (0.028) | Shingler et al. 2013 [26] | | Edema | 0.2 (0) | Assumption | | Febrile neutropenia | 0.09 (0.016) | Nafees et al. 2008 [27] | | Leucopoenia/neutropenia/neutrophils/thrombocytopenia/low platelets | 0.09 (0.015) | Nafees et al. 2008 [27] | | Liver toxicity (ALT/AST elevation) | 0 | Assumption | | Hypertension | 0.153 (0.024) | Swinburn et al. 2010 [28] | | Myalgia/muscle pain/neurotoxicity/peripheral sensory neuropathy | 0.236 (0.025) | Shingler et al. 2013 [26] | | Nausea/vomiting | 0.357 (0.026) | Shingler et al. 2013 [26] | | Pulmonary (dyspnea/pleural effusion/pneumothorax/pulmonary toxicity) | 0.242 (0.026) | Shingler et al. 2013 [26] |
|
|
AEs: adverse events; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HR: hazard ratio; OS: overall survival; PFS: progression-free survival; PPS: postprogression survival; SE: standard error.
|
